April 2009
Volume 50, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2009
Thiolated Chitosan for the Treatment of Dry Eye - Evaluation in Mice Using the Controlled-Environment Chamber Model
Author Affiliations & Notes
  • M. Hornof
    Research, Croma-Pharma GmbH, Leobendorf, Austria
  • S. Goyal
    Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts
  • R. Dana
    Schepens Eye Research Institute, Harvard Medical School, Boston, Massachusetts
  • Footnotes
    Commercial Relationships  M. Hornof, Croma-Pharma, E; S. Goyal, None; R. Dana, Croma-Pharma, F.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2009, Vol.50, 3663. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Hornof, S. Goyal, R. Dana; Thiolated Chitosan for the Treatment of Dry Eye - Evaluation in Mice Using the Controlled-Environment Chamber Model. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3663.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : The role of a new topically applied thiolated polymer - chitosan-N-acetylcysteine conjugate (chitosan-NAC) - was investigated in a mouse model of dry eye disease. It is postulated that interaction between thiol groups of the chitosan-NAC with cysteine-rich mucin (MUC5AC) increases residence time of the polymer on the ocular surface and tear film stability.

Methods: : Dry eye was induced by placing female C57BL/6 mice in a controlled-environment chamber (relative humidity below 30%, continuous airflow 15l/min) and aggravated by application of atropine and scopolamine. Fluorescein staining was used to monitor the effect of desiccating stress on the corneal surface during the study. Three topical formulations (chitosan-NAC 0.5%, chitosan-NAC 0.3% and Artelac® EDO® artificial tear containing 0.32% methylhydroxypropylcellulose as positive control) were applied in a masked fashion twice a day for 2 weeks starting 48h after induction of dry eye. An untreated dry eye group served as control. Quantitative Real-Time PCR was performed at the end of the study to evaluate TNF-, IL-1 and IL-1β expression in ocular surface tissues.

Results: : Mice treated with chitosan-NAC 0.3% showed a downward trend in corneal staining compared to the other 3 groups, which was not statistically significant. Treatment with chitosan-NAC 0.3% resulted in a significantly decreased expression of TNF- in the conjunctiva. This effect was not observed in the cornea, where only the positive control significantly decreased both TNF- and IL-1 expression.

Conclusions: : Evaluation of important molecular biomarkers of dry eye disease such as TNF- suggests that chitosan-NAC may have some protective ocular surface properties. However, clinical data as reflected by corneal fluorescein scores did not indicate statistically significant improvement of tear film stability in any of the groups tested. Future work will focus on the use of chitosan-NAC in the prevention of ocular surface damage.

Keywords: cornea: tears/tear film/dry eye • cytokines/chemokines • inflammation 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×